Back to first-pass browser

First-pass extracted concept

optogenetic therapy for retinitis pigmentosa

Candidate: concept label1 source documents5 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

The paper describes optogenetic therapy as controlling cell activity by combining genetic engineering with optical stimulation using light. In ophthalmology, it is presented as a potential treatment for retinitis pigmentosa and related retinal degenerations.

Source 1DOIPubMed

Resources required

The abstract states that optogenetic clinical studies can involve a viral vector for gene transfer and a device for light stimulation. This implies both a gene-delivery component and a light-delivery component are required.

Source 1DOIPubMed

What problem it solves

It is presented as a way to treat retinitis pigmentosa, including in patients who were blinded by the disease. The abstract notes that first clinical studies partially recovered vision.

Source 1DOIPubMed

What it does not solve

The abstract does not claim full vision restoration or resolution of the regulatory pathway. It also highlights unresolved legal issues for combined product-device studies.

Source 1DOIPubMed

Alternatives

No direct therapeutic alternative is named in the abstract. The paper instead contrasts medicinal product regulation with medical device regulation in the EU context.

Source 1DOIPubMed

Evidence Snippets

Optogenetics has potentials for a treatment of retinitis pigmentosa and other rare degenerative retinal diseases.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1clinical observationsupports2025Source 1DOIPubMed

Early clinical studies of optogenetic therapy reported partial recovery of vision in patients blinded by retinitis pigmentosa.

Quoted textsource-backed
First clinical studies are already being conducted, whereby the vision of participating patients who were blinded by retinitis pigmentosa was partially recovered.
Claim 2mechanism of actionsupports2025Source 1DOIPubMed

Optogenetic therapy controls cell activity by combining genetic engineering with optical stimulation using light.

Quoted textsource-backed
The technology allows controlling cell activity through combining genetic engineering and optical stimulation with light.
Claim 3regulatory eligibilitysupports2025Source 1DOIPubMed

Medicinal products for optogenetic therapies of retinitis pigmentosa fulfill requirements for orphan medicinal product designation, with associated regulatory and financial incentives.

Quoted textsource-backed
Medicinal products for optogenetic therapies of retinitis pigmentosa fulfill requirements for designation as orphan medicinal product, which goes along with regulatory and financial incentives.
Claim 4regulatory statussupports2025Source 1DOIPubMed

There is no prohibition or specific regulation of optogenetic methods in the European Union.

Quoted textsource-backed
There is no prohibition or specific regulation of optogenetic methods in the European Union.
Claim 5therapeutic potentialsupports2025Source 1DOIPubMed

Optogenetics has potential as a treatment for retinitis pigmentosa and other rare degenerative retinal diseases.

Quoted textsource-backed
Optogenetics has potentials for a treatment of retinitis pigmentosa and other rare degenerative retinal diseases.